Rallis India Ltd Q1 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/w2hyxat3etd30hi801d4ssh3.pdf

Key Takeaways


Crop Care: Price-Led Growth with Margin Pressure

S Nagarajan: "The final product prices, we are more governed by the cost of treatment that we are able to provide to the farmer, the competitive actions that are there. So those have been more our guiding factors, we will have to see how the whole context plays out in Q2."

Seeds: A Challenging Year, Provision Taken Early

Sanjiv Lal: "I think it is going to be a challenging year for us. Normally, Q1 is the quarter where most of the heavy lifting is done. And based on the way the season has progressed in Q1, as a matter of prudence, we have factored in certain provisions. We'll really need to see how Q2 goes before we are able to give a full year's outlook."

International Business: Strong Quarter, Cautious on Sustainability

Sanjiv Lal: "I would like to just mention that the prices are tending to be on the higher side. So once the prices soften, while the volumes may still be there, the revenues may start looking lower because of the price changes."

Supply Chain & Raw Materials: Turning the Corner

S Nagarajan: "On the supply chain front, I think, if you compare between, let's say, December end, December '21 end and June '22 end certainly we could say that things are looking a lot more sanguine than what they were at December end."

Strategic Initiatives: Registration Progress & Portfolio Expansion

Sanjiv Lal: "We've now got some positive indication on some movements that we expecting towards Q4. So in anticipation of getting the PEKK plant back on stream, we have started the overhauling of the plant so that we are ready by the end of the year for getting the plant restarted, because there is some silver lining that we see in terms of getting back into production for PEKK."

Guidance & Commitments

CommitmentSpecificsTimeline
Channel stock normalizationChannel stocks to narrow down closer to last year's levelBy H1 end
Margin normalizationHigh-cost inventory unwound; more comfortable position at weighted average levelLatter part of Q2
Metribuzin capacityPlant running at capacity; inventory worked offTowards end of Q2
Pendimethalin normalizationSituation fully normalizedTowards end of calendar year
Acephate Brazil shipmentsFormulation exports to commenceQ2 onwards
PEKK restartPlant back on stream, subject to orders materializingEnd of financial year
Seeds provision reassessmentDecision on further provisions after clarity on liquidationBy October
BRL trials commencementSubject to final regulatory approvalThis financial year
Multipurpose plant product launchNew product from new plantLatter part of this year
Export revenue mix targetExports at ~40% of revenues (from 33-34% currently)3-4 years down the line

Key Metrics

MetricQ1 FY23
Revenue₹863 cr, +16.5% YoY
EBITDA₹113 cr, vs ₹122 cr in Q1 FY22
EBITDA margin13.1%, lower by 330 bps YoY
Profit after tax₹67 cr, vs ₹82 cr in Q1 FY22
PAT margin7.8%, vs 11.1% in Q1 FY22
Crop care revenue growth26.5% YoY, 16.3% price growth and 10.2% volume growth
Domestic business revenue growth17.1% YoY, primarily price-led
International business revenue growth50.8% YoY, driven by both volume and value
Seeds business revenue₹267 cr
Seeds inventory provision₹13 cr recognized on aging-based provision
Domestic crop care price growth~14% YoY, volume growth ~2-3%
Export volume growth~25-26%, balance price growth
Export formulation mix~20% of export portfolio
Metribuzin capacity utilization55-60%
Pendimethalin capacity utilization70-75%
Acephate capacity utilizationflat out
Cotton hybrid Diggaz volume1.75 lakh packets, up from ~20,000 packets last year
Full-year capex guidance₹250 cr